Company
Chiesi
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
17
12 still marketed
Novel approvals
9
Approvals since 2021
6
Originals and new uses
Phase 3 trials
60
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Trimbow approved May 14, 2026
- Juxtapid new use Priority reviewOrphanFeb 25, 2026
- Filsuvez approved NovelPriority reviewOrphanDec 18, 2023
- Ferriprox new use OrphanApr 30, 2021
- Ferriprox new use OrphanApr 30, 2021
- Ferriprox new use OrphanApr 30, 2021
- Mycapssa approved OrphanJun 26, 2020
- Ferriprox approved Accelerated approvalOrphanMay 19, 2020
- Ferriprox new use OrphanJul 25, 2019
- Revcovi approved NovelOrphanOct 5, 2018
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07546981 · 554 participants (planned) · Start Jun 26, 2026 · Primary completion Oct 17, 2028
Drug: Experimental: Participant Group CHF 5993 pMDI HFA-152a · For: Asthma
Sites: Beijing, China · 2 sites in all
- Open-label Extension Study to Evaluate Metreleptin in Patients With Partial LipodystrophyPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06679270 · 24 participants (planned) · Start Oct 14, 2024 · Primary completion Mar 2028
Drug: Metreleptin · For: Familial Partial Lipodystrophy
Sites: Birmingham, Alabama; Boca Raton, Florida; Boston, Massachusetts · 7 sites in all
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06328608 · 22 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2028
Drug: PRX-102 1 mg/kg every two weeks · For: Fabry Disease
Sites: Phoenix, Arizona; Atlanta, Georgia; Iowa City, Iowa · 12 sites in all
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT05710692 · 16 participants (planned) · Start Aug 1, 2023 · Primary completion Oct 2027
Drug: PRX-102 1 mg/kg every 2 weeks; PRX-102 2 mg/kg every 4 weeks · For: Fabry Disease
Sites: Chikushino-shi, Japan; Sendai, Japan; Nishihara, Japan · 10 sites in all
- A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis BullosaPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06917690 · 6 participants (planned) · Start Apr 18, 2025 · Primary completion Mar 2026
Drug: Oleogel-S10 · For: Epidermolysis Bullosa; Junctional Epidermolysis Bullosa; Epidermolysis Bullosa, Dystrophic and 7 more
Sites: Fukuoka, Japan; Kobe, Japan; Niigata, Japan · 6 sites in all
Marketed drugs (12)
Newest FDA action first.
- Cardene In 4.8% Dextrose In Plastic Container Nicardipine Hydrochloride · 1992
- Juxtapid Lomitapide Mesylate · 2012
- Ferriprox Deferiprone · 2011
- Ferriprox Deferiprone · 2015
- Ferriprox Deferiprone · 2020
- Mycapssa Octreotide Acetate · 2020
- Filsuvez Birch Triterpenes · 2023
- Bethkis Tobramycin · 2012
- Kengreal Cangrelor · 2015
- Curosurf Poractant Alfa · 1999
- Cleviprex Clevidipine · 2008
- Revcovi Elapegademase-Lvlr · 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.